Acadia's $60 Million Bridge

Acadia's $60 Million Bridge

Acadia Healthcare has spent two years telling investors that the beds are coming. On Thursday, it finally put a dollar figure on what that means.

Q3 2026 revenue rose 5.1% to $895 million, same-facility revenue grew 5.2%, and adjusted EBITDA of $176.4 million came in above internal expectations. Management raised full-year guidance for the third consecutive quarter—revenue to $3.44–$3.46 billion, adjusted EBITDA to $615–625 million—and, more importantly, quantified the 2027 step-up: roughly “$60 million of incremental adjusted EBITDA from these cohorts in 2027 compared to 2026” — Debbie Osteen, Chief Executive Officer (CEO) · 2026-11-05. That is the first hard number attached to the long-promised $200 million opportunity embedded in the 16 facilities opened since 2023.

Yet the stock sits 61% below its 2022 peak. The 90-day tape is up 11%, matching a broader bid for behavioral-health services—the global theme cluster including Acadia, Elevance, and Molina has returned +53.75% over 360 days. But Acadia specifically trades at 0.8x revenue, a fraction of the 2.9x it commanded in 2022. The gap between improving operations and depressed valuation is the story.

What Actually Changed

Three things. First, the development pipeline is no longer a promise—it is open. All facilities in the development plan are now serving patients. The 144-bed Coastal Pines near Jacksonville opened in August, the fourth new acute facility this year and the 16th since 2023. Management credited a new licensure playbook for cutting approval timelines: “we've been able to dramatically cut the time that it took last year as well as years before” — Debbie Osteen, Chief Executive Officer (CEO) · 2026-11-05. That matters because every month of delay is a month of startup losses with no revenue.

Second, the startup-loss math is now explicit. The drag from facilities opened in the last 12 months was $12 million in Q3. On the call, CFO David Duckworth laid out the bridge:

our preliminary math is that we think that we can get it down from about $45 million to around $10 million... A reduction from $45 million to $10 million is our projection that is incorporated into that $60 million projection.

Third, the capital-allocation pivot is real. CapEx guidance was cut to $210–230 million for 2026, down from the $610–630 million spent in 2025 and below the already-reduced plan discussed last year. The latest filed quarter showed capital expenditure of just $39 million, down 77% year over year. Capital Expenditure That restraint is producing cash: Q3 operating cash flow was $98 million, free cash flow $47 million, and the company repaid $63 million of debt, bringing net leverage to 3.9x. This is a company shifting from growth-at-all-costs to cash generation.

The Overhangs That Explain the Discount

If the story were purely about new beds ramping, the stock would probably not be this cheap. The discount reflects three unresolved issues.

New York Medicaid. The loss of New York patients in Pennsylvania facilities cut Q3 same-facility revenue growth by roughly 1% and volume growth by 2.6%. Management says the backfill is exceeding expectations—new referral relationships in surrounding states and Pennsylvania—but the issue is not fully resolved. The keyword New York remains in the top-10 company themes, down from the very top earlier this year but still present. Until New York referrals resume or the facilities are fully backfilled, the overhang lingers.

Legal and professional liability. Government investigation costs remained elevated—an analyst pegged them around $18 million in the quarter—and the company still faces DOJ/SEC scrutiny. Management declined to guide on timing or resolution: “we are still working in collaboration, cooperating fully with the government, and so we would not have any other comment there” — Debbie Osteen, Chief Executive Officer (CEO) · 2026-11-05. The PLGL review is now conducted more frequently—mid-year and Q4—but the expense remains a swing factor. The $7 million derivatives settlement gain this quarter is a reminder that legal items can cut both ways, but they are not part of adjusted EBITDA.

Core growth is still modest. Same-facility patient days grew 1.1% in Q3; adjusting for New York, growth was 3.7%, with “legacy facilities contributed 1.6% to that 3.7%” — David Duckworth, Chief Financial Officer (CFO) · 2026-11-05. That is better than the low-single-digit baseline of the past two years, but it is not the mid-single-digit volume algorithm the company once pitched. Commercial mix fell to 20.9%, down nearly 400 basis points year over year, largely because specialty facility closures removed higher-commercial-payer business. Length of stay fell 5.1% as the mix shifted to acute—a math effect, not a demand problem, but one that keeps reported patient-day growth looking softer than admissions.

The Quiet Positive: Bad Debt Fell Off the Page

For five quarters, bad debt and payer denials dominated the Q&A. In Q3 2026, the topic barely surfaced. Bad debts and denials were stable as a percentage of revenue; the year-over-year headwind was $4 million, more than half of which was simply revenue growth. That is a meaningful change in tone. In Q3 2025, management was describing “payer friction manifest across both rate dynamics and volume” — Christopher Hunter, Chief Executive Officer · 2025-11-06. A year later, the friction has not disappeared, but it has stopped getting worse—and the keyword has dropped out of the top-30 company themes entirely.

The CTC service line is also stabilizing. Revenue of $141 million was flat sequentially, but management pointed to admission trends improving in September and October, and said cost reductions have protected earnings. CTC is 16% of revenue and operates in 33 states; it is not a growth engine yet, but it is no longer a leak.

The Demand Backdrop Is Not the Problem

Behavioral-health demand remains strong. Acadia's acute segment grew revenue 11% and volume 7.5% in the quarter. The constraint is not patients—it is execution on occupancy, payer contracts, and legal resolution. On Medicaid work requirements from the One Big Beautiful Bill, CEO Debbie Osteen said “about 50% of our Medicaid patients are in expansion states” — Debbie Osteen, Chief Executive Officer (CEO) · 2026-11-05 and that the vast majority should qualify for exemptions. That is a manageable risk, not an existential one.

The bigger question is whether the $60 million bridge is the first step of a multi-year ramp or another promise that slips. Prior calls show the pattern: in Q2 2026, management said it had “confidence in delivering on the 200 million of the incremental adjusted EBITDA” — Debbie K. Osteen · 2026-07-29; in Q2 2026, David noted startup losses had been stuck around $12 million for two quarters. The difference now is that all facilities are open, the licensure bottleneck has eased, and the loss roll-off is quantified. The burden of proof has shifted from "can they open?" to "can they fill?"

The tape suggests investors are not yet convinced. But the fundamentals are improving: revenue is flattening at a higher base, operating margin is thin but positive, and the cash flow pivot is real. The latest filed quarter showed effective net cash of -$2.3 billion, a leverage profile that still constrains flexibility. Effective Net Cash If the $60 million materializes and CapEx stays low, free cash flow should inflect, giving management room to pay down debt and narrow the valuation gap.

For now, Acadia is a show-me story with a number attached. The third consecutive raise is a good start. The next test is whether the 2027 bridge survives contact with Q4 and the February guide.